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Abstract  46 
Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are 47 
indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g., amyloid-beta peptides 48 
(Aβ42 & Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich 49 
source of potential biomarkers reflecting central nervous system pathophysiology and should 50 
be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the 51 
triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported 52 
to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that 53 
increase the likelihood of developing dementia. In this study, we measured the levels of plasma 54 
sTREM2 and plasma NFL in 48 confirmed TREM2 rare variants carriers and 49 non-carriers. 55 
Our results indicate that there are no changes in plasma sTREM2 and NFL between TREM2 56 
rare variants carriers and non-carriers. Furthermore, plasma sTREM2 is not different between 57 
healthy controls, mild cognitive impairment (MCI) or AD. In conclusion, plasma sTREM2 does 58 
not mimic the recent changes found in CSF sTREM2. 59 
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Introduction 68 
There has been considerable progress in the search for blood-based biomarkers able to capture 69 
the clinical course and underlying pathophysiology of Alzheimer’s disease (AD), for review 70 
see (1). Reduced plasma Aβ42/Aβ40 ratio (2-4) and increased neurofilament light chain (NFL) 71 
(5-7) are becoming consistently  reported in AD and, encouragingly, these findings mimic the 72 
more established observations seen in cerebrospinal fluid (CSF) (8). NFL is not a specific 73 
biomarker for AD (9). Increases are observed in a number of neurodegenerative disorders (10-74 
12), owing to its global reflection of axonal injury or degeneration. Yet, translating other co-75 
pathology markers of neurodegeneration from CSF to blood has been less successful. For 76 
example, plasma total tau (T-tau) increases in AD (13) but it seems to have limited clinical 77 
utility and phosphorylated form of tau (P-tau) has proven difficult to establish as a reliable 78 
measure in blood despite recent promise (14). Likewise, TDP-43 (15), alpha-synuclein (16) and 79 
the post-synaptic dendritic biomarker, neurogranin (17), all have substantial and specific 80 
peripheral expression but levels appear to be unrelated to changes in the central nervous system.    81 
The triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor 82 
that guides essential functions of microglia. Rare variants in TREM2 strongly increase the 83 
likelihood of developing AD, frontotemporal dementia (FTD), Parkinson’s disease (PD) and 84 
amyotrophic lateral sclerosis (ALS) (18-23). TREM2 is a type-1 transmembrane protein and its 85 
ectodomain is shed at the plasma membrane by ADAM family proteases C-terminal at histidine 86 
157 position (24-27). The resulting soluble fragment (sTREM2) is released into the 87 
extracellular space and can be found in CSF and plasma (28, 29).  Recently, the concentrations 88 
of CSF sTREM2 have been shown to be increased in early symptomatic stages of sporadic (30-89 
34) and autosomal dominant AD patients (35). Interestingly, Aβ pathology and tau-related 90 
neurodegeneration may impact levels of CSF sTREM2 differently (33). Moreover, it has been 91 
shown that the concentrations of CSF sTREM2 vary between different disease-associated 92 
TREM2 genetic variant carriers (32, 33).  93 
Unlike CSF sTREM2, levels of sTREM2 in blood have been poorly investigated. In this study, 94 
we investigate plasma concentrations of sTREM2 in patients with AD and mild cognitive 95 
impairment (MCI) compared with aged-matched healthy controls. Furthermore, in a novel 96 
approach, we also report on blood concentrations of sTREM2 and NFL in TREM2 rare variants 97 
carriers. 98 
 99 
Methods 100 
Participants 101 
Samples from a total of 97 participants were used for these analyses (Table 1). The majority of 102 
samples (n=82) were from the longitudinal AD cohorts managed at King’s College London 103 
(KCL; AddNeuroMed (36), Kings Health Partners-Dementia Case Register (KHP-DCR) a UK 104 
clinic and population based study (37) and the MRC AD Biomarker study (38)). Further 105 
samples were obtained from DEGESCO (n=11, Dementia Genetics Spanish Consortium (39, 106 
40)) and EDAR (n=4, Beta amyloid oligomers in the early diagnosis of AD and as marker for 107 
treatment response (41)). Informed consent for all participants was obtained according to the 108 
Declaration of Helsinki (1991) and protocols and procedures were approved by the relevant 109 
local ethical committee at each site. The cohorts as mentioned above were genetically analysed 110 
to identify known or novel non-synonymous variants in exon 2 of the TREM2 gene, previously 111 
linked to pathogenic risk or predicted to be detrimental. Of the 48 participants identified with a 112 
TREM2 pathogenic variant (TREM2var, Table 1), 10 were control, 10 had MCI and 28 had a 113 
dementia diagnosis (AD). Similar age-matched non-carrier control (n=10), MCI (n=8) and AD 114 
(n=31) samples were also included.  115 
 116 
Plasma measures of sTREM2 and NFL 117 
Plasma sTREM2 was measured using an in-house electrochemoluminescent assay on the 118 
MesoScale Discovery SECTOR imager 6000 (MesoScale Discovery (MSD) Maryland, US) 119 
using a method adapted from Kleinberger et al (29). The capture antibody was the biotinylated 120 
polyclonal goat anti-human TREM2 (0.25µg/mL R&D Systems, Minneapolis, US) and the 121 
detector antibody was monoclonal mouse anti-human TREM2 (1µg/Ml Santa Cruz 122 
Biotechnlogy, Texas, US). A standard curve for calculations of unknowns was constructed 123 
using recombinant human TREM2 (4000 – 62.5 pg/mL, Sino Biological, Bejiing, China) and 124 
plasma samples were diluted 1:4 before being assayed. For a more comprehensive description 125 
of the method please see (29). For NFL, the commercially available NF-light assay on an HD-126 
1 Simoa instrument (Quanterix, Lexington, MA, USA) was utilized. All biochemical analyses 127 
were performed at the Institute of Neurology at University College London (UCL). 128 
 129 
Statistical analysis 130 
Data normality was determined by the D’Agostino-Pearson test and statistical evaluation was 131 
performed on log10-transformed data. After transformation, the data followed a normal 132 
distribution. All data analysis reported has been performed on log10-transformed sTREM2 and 133 
NFL but the untransformed values are shown in descriptive tables and figures. To study the 134 
association of plasma measures with demographic data a Pearson product-moment correlation 135 
was utilized for age and MMSE whereas t-test (sTREM2) or a one-way analysis of covariance 136 
(ANCOVA, NFL) for gender and APOE status. Only age was a significant predictor of plasma 137 
NFL, the subsequent analyses were therefore conducted including age as a confounder. A t-test 138 
or ANCOVA were conducted to determine clinical group differences between blood 139 
biomarkers. ANCOVA analyses were followed by a Bonferroni corrected post hoc pairwise 140 
comparison where appropriate. A partial correlation, adjusted by age, tested the association 141 
between plasma sTREM2 and plasma NFL. Statistical analysis was performed using IBM SPSS 142 
Statistics, version 25 (Armonk, NY, USA). 143 
 144 
Results 145 
Forty-eight confirmed TREM2 rare variant carriers and 49 non-carriers where included in the 146 
study. The TREM2 rare variant carrier group comprised of 10 different variants: p.Q33X, 147 
p.D39N, p.R47H, p.P59L, p.R62H, p.D87N, p.T96K, p.Q691H, p.H703Y and p.L868R. The 148 
demographical characteristics of the cohort are described in Table 1. There were no differences 149 
in age between TREM2 rare variant carriers (M = 75.2, SD = 7.3) and non-carriers (M = 76.1, 150 
SD = 6.7). The inclusion of gender was very similar across groups (carriers, 26/48 female 151 
[54.2%]; non-carriers, 27/49 female [55.1%]). Finally, there was no statistically significant 152 
differences in MMSE (carriers, M = 23.1, SD = 6.4; non-carriers, M = 23.3, SD = 5.0) or clinical 153 
diagnosis between the two groups (Table 1). 154 
In the whole cohort, plasma sTREM2 was not associated with age (r = 0.060; P = 0.562), gender 155 
(P = 0.083), APOE ε4 status (P = 0.237) or MMSE (r = -0.018; P = 0.858). There were no 156 
differences in the levels of plasma sTREM2 between TREM2 rare variant carriers (M = 7,346 157 
ng/L, SD = 5,526 ng/L) or non-carriers (M = 8,750 ng/L, SD = 5,265 ng/L), t(95) = 1.696, P = 158 
0.093 (Fig. 1A). There were no significant differences in plasma sTREM2 between carriers of 159 
different TREM2 rare variants (F(3, 84) = 1.68, P = 0.177, Fig 1B). Note, we only included 160 
TREM2 rare variants with >2 individuals per group in this analysis. Adding clinical diagnosis 161 
as covariate did not change the result (P = 0.171). Next, we tested whether plasma sTREM2 162 
levels differ between clinical diagnoses, regardless of the TREM2 rare variant status, between 163 
AD (M = 8,859 ng/L, SD = 5,951 ng/L), MCI (M = 6,204 ng/L, SD = 2,572 ng/L) and controls 164 
(M = 7,352 ng/L, SD = 5,318 ng/L). Plasma sTREM2 levels were not different between these 165 
groups (F(2, 94) = 1.84, P = 0.164, Fig 1C). Adjusting for the effect of age and gender did not 166 
change the result of sTREM2 in plasma. 167 
As expected, plasma NFL concentrations were significantly associated with age (r = 0.202, P = 168 
0.047). After accounting for the effect of age, plasma NFL levels were found to be associated 169 
with MMSE (r = -0.353, P = 0.0004), and tended to be higher in females (M = 25.6, SD = 13.1 170 
ng/L) compared to males (M = 25.1, SD = 22.8 ng/L; P = 0.079). Levels were not affected by 171 
APOE ε4 status (P = 0.899). There were no differences in plasma NFL between TREM2 rare 172 
variant carriers (M = 24.6 ng/L, SD = 19.1 ng/L) and non-carriers (M = 26.1 ng/L, SD = 17.1 173 
ng/L) (F(1, 94) = 0.505, P = 0.479, Fig 2A), after adjusting for the effect of age. Similar to 174 
plasma sTREM2, there were no differences in plasma NFL when comparing the different 175 
TREM2 rare variants (F(3, 83) = 0.113, P = 0.952, Fig 2B). This remained true when correcting 176 
for the effect of the clinical diagnosis (P = 0.633). As expected, differences in plasma NFL were 177 
observed between the three clinical groups (F(2, 93) = 4.89, P = 0.010). Bonferroni corrected 178 
post hoc pairwise comparison demonstrated that the AD group (M = 29.0 ng/L, SD = 21.6 ng/L) 179 
had significantly higher levels of NFL compared to controls (M = 18.8 ng/L, SD = 7.2 ng/L; P 180 
= 0.025) but not to MCI (M = 20.5 ng/L, SD = 8.1 ng/L; P = 0.096, Fig 2C). A further 181 
adjustment for the effect of gender did not change these NFL findings. 182 
In the whole cohort, when correcting for age, a significant positive correlation between plasma 183 
sTREM2 and plasma NFL was observed (r = 0.245, P = 0.016). However, this correlation is 184 
driven by the symptomatic individuals (MCI and AD) as no significant association of plasma 185 
sTREM2 and plasma NFL was observed in the control group (r = 0.250, P = 0.302) but a 186 
tendency in the symptomatic group (r = 0.223, P = 0.053). 187 
 188 
Discussion 189 
This is the first study to have comprehensively investigated if the levels of plasma sTREM2 190 
and an neurodegenerative marker, plasma NFL, differ between TREM2 rare variant carriers and 191 
non-carriers. Our main finding demonstrates that there are no significant differences in plasma 192 
sTREM2 and NFL between these groups. Furthermore, we also show that plasma sTREM2 193 
does not differ between controls, MCI and AD.  194 
While sTREM2 has been extensively studied in CSF, only a few studies have reported sTREM2 195 
in blood. Piccio and co-workers (28) demonstrated that serum sTREM2 levels did not differ 196 
between multiple sclerosis, other inflammatory neurologic diseases and non-inflammatory 197 
controls. Kleinberger et al. (29) found no difference in plasma sTREM2 between healthy 198 
controls, AD and FTD. The lack of separation between AD and controls was then independently 199 
replicated (32). In a different approach, Ohara et al. showed that increased serum sTREM2 is 200 
associated with increased risk to develop dementia in Japanese population (42). Herein, we also 201 
demonstrate that plasma sTREM2 is not different between TREM2 rare variant carriers and 202 
non-carriers, nor with respect to clinical diagnosis. Therefore, although readily detectable, 203 
sTREM2 in blood is not useful to discriminate those people with a clinical diagnostic group, or 204 
those with a TREM2 variant associated with AD. It should be noted that sTREM2 in blood most 205 
likely has a peripheral rather than a central nervous system (CNS) origin from microglia. This 206 
is in agreement with the ubiquitous expression pattern of TREM2 at both mRNA and protein 207 
levels in Human Protein Atlas (https://www.proteinatlas.org/ENSG00000095970-208 
TREM2/tissue). TREM2 is highly expressed in cells from a myeloid lineage, such as 209 
monocytes, macrophages, Kupffer cells or osteoclasts (43-46). 210 
Previously, it was shown that both plasma and CSF sTREM2 were useful to detect those with 211 
homozygous TREM2 mutations (e.g. p.T66M, p.W198X, p.Q33X and p.Y38C) that lead to 212 
Nasu-Hakola disease or an FTD-like syndrome (47, 48). In these diseases, sTREM2 in blood 213 
or CSF is almost absent, which is in line with the impaired cell surface transport and shedding 214 
that occur with these mutations (29, 49). In contrast, heterozygous TREM2 rare variant carriers 215 
have a less obvious and inconsistent pattern of CSF sTREM2. While the TREM2 p.R47H rare 216 
variant is associated with increased CSF sTREM2, other TREM2 variants (e.g. p.L211P; 217 
T96K/L211P/W191X) have been reported to be associated with decreased or unchanged levels 218 
of CSF sTREM2 (e.g. R62H) (32, 33) (Deming et al. Sci Trans Med 2019 in press). Our 219 
findings could be explained by how these rare variants differently affect the processing and 220 
shedding of TREM2. For example, individual variants are believed to impact TREM2 221 
production (Q33X), expression or turnover at the cell surface (R47H) (29, 50), α-secretase 222 
cleavage of the extracellular soluble ectodomain (H157Y) (27, 51) and/or ligand binding 223 
(R47H, R62H, T96K, H157Y) (52-54). Surprisingly, we did not find such differences in 224 
plasma, suggesting a different regulation of TREM2 in the periphery and the CNS. We also 225 
investigated plasma NFL, but here we also found no differences between TREM2 rare variant 226 
carriers and non-carriers, even when introducing clinical diagnosis as a co-variable, suggesting 227 
that the neuronal injury is no different in AD irrespective of whether someone has a TREM2 228 
rare variant. These findings are agreement with clinical data that find AD cases with a TREM2 229 
p.R47H rare variant are clinically indistinguishable from other AD, albeit those with a TREM2 230 
rare variant generally have an earlier age of onset (55). Finally, the finding that sTREM2 is 231 
associated with NFL in AD is consistent with the association of CSF sTREM2 with T-tau, 232 
another marker of neurodegeneration, and suggests that inflammatory response might be 233 
coupled to neurodegeneration (56). 234 
This study has some limitations. Despite the remarkable number of individuals with rare 235 
variants that were included, some individual variants were represented by only very small 236 
numbers, which precluded a comparison between them. Additionally, these samples did not 237 
have the core AD CSF biomarkers to confirm diagnosis, disease stage or link analyses 238 
individually to Tau or amyloid burden, and hence we were limited to using clinical diagnosis. 239 
The main strengths are the fact that we used very reliable and well-established assays for both 240 
sTREM2 and NFL. The study was designed in such a way that an important total number of 241 
TREM2 rare variants were carefully matched to a control group in terms of age, gender and 242 
clinical diagnosis. 243 
In conclusion, this study, for the first time, demonstrates that the levels of sTREM2 and NFL 244 
in plasma do not differ between TREM2 rare variants carriers and non-carriers. Furthermore, 245 
we confirm previous reports that sTREM2 is not changed in AD or MCI compared with aged-246 
matched controls. Therefore, we conclude that, although plasma sTREM2 may be useful to 247 
detect TREM2 homozygous mutations, plasma sTREM2 is not a reliable biomarker to detect 248 
TREM2 rare variant status nor suspected AD.  249 
 250 
Figure legends 251 
 252 
Fig 1. The concentrations of plasma sTREM2. No change in the levels of sTREM2 between 253 
TREM2 rare variant carriers and non-carriers (A, B). A non-significant increase in sTREM2 254 
was observed in AD patients compared to MCI and aged-matched controls (C). 255 
 256 
Fig 2. The concentrations of plasma NFL. No change in the concentrations of NFL between 257 
TREM2 rare variants and non-carriers (A, B). A significant increase in NFL was observed in 258 
AD patients compared to MCI and aged-matched controls which was not influenced by TREM2 259 
mutation status (C).  260 
 261 
 262 
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 503 
 504 
Table 1. Demographic and clinical characteristics of TREM2 rare variant carriers and non-505 
carriers  506 
 
TREM2  
non-carriers 
(n=49) 
TREM2 rare 
variant carriers  
(n=48) 
TREM2 rare variant carriers  
p.R47H 
(n=26) 
p.T96K 
(n=8) 
p.D87N 
(n=5) 
Others  
(n=9) 
Age, years (SD) 76.1 (6.7) 75.2 (7.3) 73.9 (8.4) 76.6 (4.8) 72.4 (6.8) 76.9 (4.1) 
Female, n (%) 27/49 (55.1) 26/48 (54.2) 12 (46.2) 5 (55.5) 3 (60) 6 (75) 
APOE ɛ4 
carriers, n (%) 
24 (68.6) a 21 (59.7) b 11 3 1 6 
MMSE, n (SD) 23.3 (5.0) 23.1 (6.4) 21 (7.5) 25 (5.0) 28.8 (4.5) 24.7 (2.3) 
Diagnosis, n (%) 
AD, 31/49 (63.3) 
MCI, 8/49 (16.3) 
Ctrl, 10/49 (20.4) 
AD, 28/48 (58.4) 
MCI, 10/48 (20.8) 
Ctrl, 10/48 (20.8) 
18/26 (69) 
4/26 (15.5) 
4/26 (15.5) 
2/9 (25.0) 
3/9 (37.5) 
3/9 (37.5) 
1/5 (16.7) 
2/5 (33.3) 
2/5 (50.0) 
7/9 (87.5) 
1/9 (12.5) 
0/9 
sTREM2, ng/L 
(SD) 
8,750 (5,265) 7,346 (5,526) 7,294 (6791) 8,761.8 (4840) 6,431 (4107) 7,009 (1889) 
NFL, ng/L (SD) 26.1 (17.1) 24.6 (19.1) 25.7 (23.8) 25.2 (17.8) 23.1 (7.7) 21.3 (7.6) 
